#USA #New York #Neuromodulation #tAN Technology #Spark Biomedical

Spark Biomedical Unveils New Research at the 2026 NYC Neuromodulation Conference

Spark Biomedical, a pioneering company in bioelectronic medicine, is set to present at the upcoming 2026 NYC Neuromodulation Conference. This innovative event, scheduled from July 30 to August 3 at The City College of New York, will highlight the company's latest advancements in transcutaneous auricular neurostimulation (tAN®) technology.

At the conference, Spark Biomedical will occupy Booth #8, where they will unveil important findings from both clinical and preclinical studies. These findings demonstrate the extensive applicability of their tAN technology across various medical indications, asserting its role in treating a range of physiological systems effectively.

Key Presentations at the Conference

Alejandro Covalin, Chief Technical Officer and Co-Founder, along with a team of experts, will engage in multiple panel discussions. Notably, one session titled "Funding and Regulatory Agencies and Industry Perspectives" is scheduled for Thursday, July 30, from 11:00 a.m. to 12:00 p.m. Another significant panel, "Frontiers in Sub-Cortical and Peripheral Stimulation for Addiction Treatment From Mechanism to Impact," will take place later the same day, from 2:15 p.m. to 3:30 p.m.

Dr. Chris Czura, Senior Director of Scientific Affairs, is also set to participate in a panel focused on women's health, showcasing how neurotechnologies can impact this crucial area of healthcare.

Scientific Posters and Studies

The company will present several important scientific posters throughout the event. Highlights include:

• - "Wearable Auricular Neurostimulation Modulates Acute Stress Physiology and Symptom Response in a Randomized Sham-Controlled Study" by Michael Darrow, Director of Research Innovations. This poster will be available in Session B on August 1.
• - "Wearable Auricular Neurostimulation Improves Stress Resilience and Sleep in First Responders Decentralized Clinical Trial Results" by Caroline Benner, Director of Clinical Affairs, presented on August 2.
• - "Neuromodulation Reduces Hemorrhage in a Swine Model of Non- compressible Liver Injury" presented by Dr. Chris Czura, with specific session details to be announced.

Navid Khodaparast, PhD, the Chief Science Officer and Co-founder, reflected on the significance of this event by stating, "NYC Neuromodulation 2026 provides an essential platform for demonstrating how tAN technology is evolving beyond traditional single-indication treatments. The diverse range of research we showcase — from enhancing stress resilience to controlling hemorrhage — underscores the extensive potential of targeted auricular neurostimulation."

Looking Ahead

Attendees are encouraged to visit Spark Biomedical’s booth throughout the conference to learn more about their groundbreaking neurostimulation device, the Sparrow Link, and their ongoing research initiatives. Through their targeted approach, Spark Biomedical is committed to broadening the horizons of treatment options available in neuro-behavioral health and beyond.

Established in Dallas, Texas, Spark Biomedical is on the cutting edge of developing wearable bioelectronic therapies driven by its proprietary tAN platform. With a focus on various health conditions including neuro-behavioral, neuro-vascular, and neuro-immune disorders, the company is poised to make significant contributions to the field of medical technology.

For more information about Spark Biomedical and its innovative solutions, you can visit their website at www.sparkbiomedical.com.

This event represents a crucial opportunity to witness the future of neuromodulation, opening doors for discussions and developments that could redefine treatment methodologies in the years to come.